# Safety and Effectiveness of BENLYSTA (Belimumab) in Systemic Lupus Erythematosus (SLE) Registry

> **NCT01729455** · — · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 3138 (actual)

## Conditions studied

- Systemic Lupus Erythematosus

## Interventions

- **BIOLOGICAL:** Benlysta
- **OTHER:** Standard of Care (SoC) Therapy

## Key facts

- **NCT ID:** NCT01729455
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2013-02-21
- **Primary completion:** 2025-02-28
- **Final completion:** 2025-02-28
- **Target enrollment:** 3138 (ACTUAL)
- **Last updated:** 2026-03-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01729455

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01729455, "Safety and Effectiveness of BENLYSTA (Belimumab) in Systemic Lupus Erythematosus (SLE) Registry". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01729455. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*